Literature DB >> 15977246

Hepatitis C virus infection in 2,744 hemodialysis patients followed regularly at nine centers in Hiroshima during November 1999 through February 2003.

Junko Kumagai1, Yutaka Komiya, Junko Tanaka, Keiko Katayama, Yorimitsu Tatsukawa, Noriaki Yorioka, Yuzo Miyakawa, Hiroshi Yoshizawa.   

Abstract

Patients on maintenance hemodialysis (HD) are at increased risk of infection with hepatitis C virus (HCV). A prospective follow-up study on HCV infection from November 1999 to February 2003 was conducted in nine hemodialysis (HD) units in Hiroshima. A total of 2,744 HD patients were surveyed regularly for HCV RNA in serum. The prevalence of HCV RNA decreased from 15.7% (262/1,664) on the first survey to 12.9% (242/1,882) in the last one (P<0.05). This decrease may be attributed to the inclusion of patients with a lower prevalence of HCV RNA compared to patients leaving dialysis centers (111/1,080 [10.3%] vs. 132/862 [15.3%], P<0.01). During the 40 months of this study, 16 de novo HCV infections were documented in the nine HD units corresponding to an incidence of 0.33% per year. These cases included eight new HCV infections, three re-infections, and five infections that presumably occured in the window period when tested during the first survey. Our study shows that the annual incidence of de novo HCV infection during HD was 0.33%, and emphasizes the need for frequent serum HCV RNA testing and for stringent disinfection procedures in order to prevent the transmission of HCV in these settings. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15977246     DOI: 10.1002/jmv.20389

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  6 in total

Review 1.  Management of hepatitis C in patients with chronic kidney disease.

Authors:  Roberto J Carvalho-Filho; Ana Cristina C A Feldner; Antonio Eduardo B Silva; Maria Lucia G Ferraz
Journal:  World J Gastroenterol       Date:  2015-01-14       Impact factor: 5.742

2.  A shield against a monster: Hepatitis C in hemodialysis patients.

Authors:  Seyed-Moayed Alavian
Journal:  World J Gastroenterol       Date:  2009-02-14       Impact factor: 5.742

3.  Clinical significance of alanine aminotransferase levels and the effect of ursodeoxycholic acid in hemodialysis patients with chronic hepatitis C.

Authors:  Chika Nishida; Hirofumi Uto; Makoto Oketani; Koki Tokunaga; Tsuyoshi Nosaki; Mayumi Fukumoto; Manei Oku; Atsushi Sogabe; Akihiro Moriuchi; Akio Ido; Hirohito Tsubouchi
Journal:  J Gastroenterol       Date:  2009-11-05       Impact factor: 7.527

Review 4.  Updated Pathway to Micro-elimination of Hepatitis C Virus in the Hemodialysis Population.

Authors:  Arun Rajasekaran; Ricardo A Franco; Edgar T Overton; Brendan M McGuire; Graham C Towns; Jayme E Locke; Deirdre L Sawinski; Emmy K Bell
Journal:  Kidney Int Rep       Date:  2021-04-25

5.  Seropositivity for anti-HCV core antigen is independently associated with increased all-cause, cardiovascular, and liver disease-related mortality in hemodialysis patients.

Authors:  Masaki Ohsawa; Karen Kato; Kozo Tanno; Kazuyoshi Itai; Yosuke Fujishima; Akira Okayama; Tanvir Chowdhury Turin; Toshiyuki Onoda; Kazuyuki Suzuki; Motoyuki Nakamura; Kazuko Kawamura; Takashi Akiba; Kiyomi Sakata; Tomoaki Fujioka
Journal:  J Epidemiol       Date:  2011-10-15       Impact factor: 3.211

6.  Standardized prevalence ratios for chronic hepatitis C virus infection among adult Japanese hemodialysis patients.

Authors:  Masaki Ohsawa; Karen Kato; Kazuyoshi Itai; Kozo Tanno; Yosuke Fujishima; Ryuichiro Konda; Akira Okayama; Koichi Abe; Kazuyuki Suzuki; Motoyuki Nakamura; Toshiyuki Onoda; Kazuko Kawamura; Kiyomi Sakata; Takashi Akiba; Tomoaki Fujioka
Journal:  J Epidemiol       Date:  2009-10-31       Impact factor: 3.211

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.